Trial Profile
Posttransplant Vorinostat therapy for the prevention of early relapse after allogeneic stem cell transplantation against mycosis fungoides/Sezary syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2016
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Allogeneic stem cell therapy
- Indications Mycosis fungoides
- Focus Adverse reactions
- 22 Nov 2016 Status changed from recruiting to completed.
- 20 Jun 2013 New trial record